PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
EBIT growth above 1.5x AGEN's 27.52%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
94.20%
Operating income growth above 1.5x AGEN's 27.52%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
94.81%
Net income growth above 1.5x AGEN's 24.62%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
98.22%
EPS growth above 1.5x AGEN's 24.50%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
98.22%
Diluted EPS growth above 1.5x AGEN's 24.50%. David Dodd would see if there's a robust moat protecting these shareholder gains.
200.00%
Share count expansion well above AGEN's 0.20%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
200.00%
Diluted share change of 200.00% while AGEN is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
12.59%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
12.59%
FCF growth above 1.5x AGEN's 1.13%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
66.67%
Positive BV/share change while AGEN is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.